A case of lenalidomide-induced hypersensitivity pneumonitis

Onkologie

Volumn 33, Issue 5, 2010, Pages 249-252

  Lerch, Erika ^a   Györik, Sandor ^b   Feilchenfeldt, Jonas ^a   Mazzucchelli, Luca ^c   Quadri, Franco ^b  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b Internal Medicine   (Switzerland)

^c Pathology Institute Canton Ticino   (Switzerland)

Author keywords

Lenalidomide; Myeloma; Pulmonary toxicity

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; LEVOFLOXACIN; MELPHALAN; PREDNISONE; PROCALCITONIN; THALIDOMIDE; TIOTROPIUM BROMIDE; VINCRISTINE;

AGED; ALLERGIC PNEUMONITIS; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL; EOSINOPHILIA; FATIGUE; FEVER; HUMAN; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG LAVAGE; LUNG TOXICITY; LYMPHOCYTE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYOPATHY; NEUTROPHIL; OXYGEN SATURATION; SENSORY NEUROPATHY; THERAPY DELAY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; WHEEZING;

AGED; ALVEOLITIS, EXTRINSIC ALLERGIC; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; HUMANS; LUNG; MALE; MULTIPLE MYELOMA; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953172726     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000305213     Document Type: Article

References (32)

1. Dimopoulos M, Spencer A, Attal M, Prince HM, et al.: Lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2124-2132.
2. Weber DM, Chen C, Niesvizky R, Wang M, et al.: Lenalidomide and dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
3. Richardson PG, Blood E, Mitsiades CS, Jagannath S, et al.: A phase II trial randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464.
4. Hideshima T, Chauhan D, Shima Y, Raje N, et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
5. Richardson PG, Schlossman RL, Weller E, Hideshima T, et al.: Immunemodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
6. Camus P, Fanton A, Bonniaud P, Camus C, et al.: Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-326. (Pubitemid 39179164)
7. Sunderij R, Kanji Z, Gin K, et al.: Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can J Cardiol 2000;16:1435-1440.
8. Ernawati DK, Stafford L, Hughes JD: Amiodarone- induced pulmonary toxicity. Br J Clin Pharmacol 2008;66:82-87.
9. Salaffi F, Manganelli P, Carotti M, Subiaco S, et al.: Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997;16:296-304.
10. Champion L, Stern M, Israël-Biet D, Mamzer-Bruneel MF, et al.: Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006;144:505-509.
11. Welte T, Hamm H, Fabel H: Mesalazine alveolitis. Lancet 1991;338:1273.
12. Savage RL, Highton J, Boyd IW, Chapman P: Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006;36:162-169.
13. Suissa S, Hudson M, Ernst P: Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-1439.
14. Quintas-Cardama A, Pérez-Encinas M, Gonzalez S, Bendaña A,: Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia. Ann Hematol 1999;78:187-188.
15. Rosado MF, Donna E, Ahn YS: Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3173.
16. Raqhavan M, Mazer MA, Brink DJ: Severe hypersensitivity pneumonitis associated with anagrelide. Ann Pharmacother 2003;37:1228-1231.
17. Sleijfer S: Bleomycin-induced pneumonitis. Chest 2001;120:617-624.
18. Collis CH: Lung damage from cytotoxic drugs. Cancer Chemother Pharmacol 1980;4:17-27.
19. Wang GS, Yang KY, Perng RP: Life-threatening hypersensitivity pneumonitis induced by docetaxel. Br J Cancer 2001;85:1247-1250.
20. Read WL, Mortimer JE, Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-853.
21. Gupta N, Ahmed I, Steinberg H, Patel D, et al.: Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002;25:96-100.
22. Barlesi F, Villani P, Doddoli C, Gimenez C, et al.: Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91.
23. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, et al.: Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003;40:79-84.
24. Steiger D, Bubendorf L, Oberholzer M, Tamm M, et al.: Ciprofloxacin-induced acute interstitial pneumonitis. Eur Respir J 2004;23:172-174.
25. Chew GY, Hawkins CA, Cherian M, Hurwitz M: Roxithromycin induced hypersensitivity pneumonitis. Pathology 2006;38:475-477.
26. Oddo M, Liaudet L, Lepori M, Broccard AF, et al.: Relapsing acute respiratory failure induced by minocycline. Chest 2003;123:2146-2148.
27. Miyakoshi S, Kami M, Yuji K, Matsumura T, et al.: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492-3494.
28. Carrion Valero F, Bertomeu González V: Lung toxicity due to thalidomide. Arch Bronconeumol 2002;38:492-494.
29. Tabata C, Tabata R, Kadokawa Y, Hisamori S, et al.: Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007;179:708-714.
30. Costabel U, Guzman J: Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001; 7:255-261.
31. Taniuchi N, Ghazizadeh M, Enomoto T, Matsuda K, et al.: Evaluation of fractional analysis of bronchoalveolar lavage combined with cellular morphological features. Int J Med Sci 2009;6:1-8.
32. Thornburg A, Abonour R, Smith P, Knox K, et al.: Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest 2007; 131:1572-1574.